Zhitong Finance App News, Shisi Pharmaceutical Group (02005.HK) issued an announcement. The group has obtained drug production registration approval from the China State Drug Administration for gadobutol injection (7.5ml: 4.5354g), which is a Class 4 chemical drug, which is considered to have passed the consistency evaluation. Gadobutrol injection is mainly used for diagnosis, for intravenous administration only. It is suitable for adults and children of all ages (including full-term neonates). It is mainly used for contrast-enhanced magnetic resonance imaging (CE-MRI) examination of all parts of the body (including head and spinal cord), and contrast-enhanced magnetic resonance angiography (CE-MRA) examination of all parts of the body.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.